Comparing Post-Operative Analgesic Effects of PCAM With Dexmedetomidine 1 mcg/ml vs PCAM With Dexmedetomidine 2 mcg/ml

NCT ID: NCT05288738

Last Updated: 2022-03-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 68 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-09
• Study Completion Date: 2021-01-10

Brief Summary

PCA morphine have been a common method in providing excellent analgesia for post-operative period. However, the usage of morphine is not without any side effects such as nausea, vomiting, respiratory depression, and over sedation.

Many adjunct have been used in combination with morphine to observe the opioid sparing effects at the same time providing good analgesia.

Dexmedetomidine is a potent and selective alpha-2 receptor agonist with sedative, anxiolytic, sympatholytic, and analgesic effects. As dexmedetomidine and morphine act via different mechanism, this combination produces synergistic analgesic effects.

The objective of our study was to observe the effectiveness in pain relief between two low concentration of dexmedetomidine (2 mcg/ml versus 1 mcg/ml) as an adjunct to PCA morphine 1 mg/ml.

Detailed Description

This was a double-blinded prospective randomised study conducted in Universiti Kebangsaan Malaysia Medical Centre from January 2020 till November 2020. This study was approved by Dissertation Committee of the Department of Anaesthesiology and Intensive Care, Universiti Kebangsaan Malaysia Medical Centre (UKMMC) and Medical Research and Ethics Committee of UKMMC.

Consent was taken during preoperative visit whereby patients were counselled on the use of PCA machine and assessment of pain score using visual analogue scale (VAS). All patients were not given sedative premedication before surgery. Induction of general anaesthesia was with IV fentanyl 2 mcg/kg, IV propofol 2 mg/kg and paralysed with IV rocuronium 0.6 mg/kg. Patients were given IV dexamethasone 0.2 mg/kg for postoperative nausea and vomiting (PONV) prophylaxis. Anaesthesia was maintained with sevoflurane to achieve MAC of 1.0 with oxygen and air in 1:1 ratio. All patients received IV morphine 0.1mg/kg intraoperatively, and surgical site infiltrated with levobupivacaine 0.5% 2 mg/kg. IV granisetron 1 mg was given to all patients at the end of the surgery and reversal was with IV neostigmine 0.05 mg/kg and IV atropine 0.02 mg/kg.

All patients were connected to the PCA morphine with test drugs after arrival in the recovery area. Patients were encouraged to self-administer the PCA whenever required. In an event of uncontrolled pain, rescue analgesia was with IV fentanyl 20 mcg boluses. All patients upon discharged to ward from recovery bay must have pain score (VAS) of less than 4, respiratory rate more than 10, MAP > 65 mmHg and HR > 60 beats/minute.

Patients were followed up at 6, 12, and 24 hours after surgery to look at the cumulative PCA morphine usage, incidence of nausea and vomiting, sedation score, respiratory depression (respiratory rate < 10 breath/min/). Side effects from dexmedetomidine namely hypotension (MAP < 65) and bradycardia (HR < 60) were also documented. The severity of nausea and vomiting was defined as mild, moderate, or severe while sedation was assessed according to five levels: 0, 1, 2, 3 and 4.

The power calculation for this study was based on a pilot study observing PCA consumption in the first 24 hours after surgery, with a mean difference, 14.67 and pooled standard deviation 20.27 in regard to dosage delivered comparing PCA morphine with dexmedetomidine 1 mcg/ml to PCA morphine with dexmedetomidine 2 mcg/ml. A group of 34 subjects each would be needed for a study with an alpha level of 0.05 (two-tailed) and a beta level of 0.2 (80% power) including 10% dropout rate.

Data were analysed using IBMR SPSSRs Statistics MacOS version 26.0 (IBM Corporation, New York, United States of America). The results were presented as frequency (percentage) and standard deviation whenever appropriate. The cumulative PCA morphine and dexmedetomidine usage pain score was analysed using the Mann-Whitney U-test. The incidence of sedation and PONV was analysed using Chi-square. Heart rate and blood pressure were analysed using independent T-test. A probability level of < 0.05 was considered to be statistically significant.

Conditions

Post-Operative Analgesia; Opioid Use, Unspecified; Laparotomy Surgery

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: DOUBLE

Study Groups

Group D1

PCA morphine 1mg/ml

Group Type: ACTIVE_COMPARATOR

Dexmedetomidine 1 mcg/ml

Intervention Type: DRUG

34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 1 mcg/ml

Group D2

PCA morphine 1mg/ml

Group Type: ACTIVE_COMPARATOR

Dexmedetomidine 2 mcg/ml

Intervention Type: DRUG

34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 2 mcg/ml

Interventions

Dexmedetomidine 1 mcg/ml

34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 1 mcg/ml

Intervention Type: DRUG

Dexmedetomidine 2 mcg/ml

34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 2 mcg/ml

Intervention Type: DRUG

Other Intervention Names

Precedex; Precedex

Eligibility Criteria

Inclusion Criteria

• ASA 1 & 2 patient
• going for elective or emergency laparotomy surgery

Exclusion Criteria

• patient with known allergy to morphine or dexmedetomidine
• Creatinine clearance less then 30ml/min
• Current alcohol dependency
• Psychiatric illness on regular sedative-hypnotic drugs
• significant obstructive sleep apnoea (OSA)
• Chronic pain patient who on regular opioids

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Universiti Kebangsaan Malaysia Medical Centre

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yeoh Chih Nie, MMed

Role: PRINCIPAL_INVESTIGATOR

Universiti Kebangsaan Malaysia Medical Centre

Locations

Universiti Kebangsaan Malaysia Medical Center

Cheras, Kuala Lumpur, Malaysia

Countries

Malaysia

Other Identifiers

FF-2019-543

Identifier Type: -

Identifier Source: org_study_id